H.C. Wainwright analyst Robert Burns initiated coverage of Kineta with a Buy rating and $8 price target. Kineta is a clinical-stage biotechnology company focused on developing next generation immuno-oncology medicines, with principal emphasis on the VISTA and CD27 targets, the analyst tells investors in a research note. The firm says Kineta’s assets are aimed at addressing immunosuppression and T-cell exhaustion, which plays a key role in determining the impact of immune system activation against tumor cells.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KA:
- Kineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Kineta prices 1.43M shares at $4.21 in registered direct offering
- Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Kineta provides new data on VISTA biomarker and KVA12123 Phase 1/2 data
- Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023
